Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 393

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2

Open access
Yang, Shouhui, He, Peijun, Wang, Jian, Schetter, Aaron, Tang, Wei, Funamizu, Naotake, Yanaga, Katsuhiko, Uwagawa, Tadashi, Satoskar, Abhay R., Gaedcke, Jochen, Bernhardt, Markus, Ghadimi, B. Michael, Gaida, Matthias M., Bergmann, Frank, Werner, Jens, Ried, Thomas, Hanna, Nader, Alexander, H. Richard, Hussain, S. Perwez·2016·Cancer Research

Abstract

Pancreatic cancers with aberrant expression of macrophage migration inhibitory factor (MIF) are particularly aggressive. To identify key signaling pathways that drive disease aggressiveness in tumors with high MIF expression, we analyzed the expression of coding and noncoding genes in high and low MIF-expressing tumors in multiple cohorts of pancreatic ductal adenocarcinoma (PDAC) patients. The key genes and pathways identified were linked to patient survival and were mechanistically, functionally, and clinically characterized using cell lines, a genetically engineered mouse model, and PDAC patient cohorts. Here, we report evidence of a novel MIF-driven signaling pathway that inhibits the orphan nuclear receptor NR3C2, a previously undescribed tumor suppressor that impacts aggressiveness and survival in PDAC. Mechanistically, MIF upregulated miR-301b that targeted NR3C2 and suppressed its expression. PDAC tumors expressing high levels of MIF displayed elevated levels of miR-301b and reduced levels of NR3C2. In addition, reduced levels of NR3C2 expression correlated with poorer survival in multiple independent cohorts of PDAC patients. Functional analysis showed that NR3C2 inhibited epithelial-to-mesenchymal transition and enhanced sensitivity to the gemcitabine, a chemotherapeutic drug used in PDAC standard of care. Furthermore, genetic deletion of MIF disrupted a MIF–mir-301b–NR3C2 signaling axis, reducing metastasis and prolonging survival in a genetically engineered mouse model of PDAC. Taken together, our results offer a preclinical proof of principle for candidate therapies to target a newly described MIF–miR-301b–NR3C2 signaling axis for PDAC management. Cancer Res; 76(13); 3838–50. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-2841

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 393

Metadata

Authors
Yang, S., He, P., Wang, J., Schetter, A., Tang, W., Funamizu, N., Yanaga, K., Uwagawa, T., Satoskar, A. R., Gaedcke, J., Bernhardt, M., Ghadimi, B. M., Gaida, M. M., Bergmann, F., Werner, J., Ried, T., Hanna, N., Alexander, H. R., & Hussain, S. P.
Venue
Cancer Research
Published
2016-06-30
Volume
76
Issue
13
Pages
3838-3850
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2336715782
Cited by
393
References
30
FWCI
8.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2841
The paper
Yang, S., He, P., Wang, J., Schetter, A., Tang, W., Funamizu, N., Yanaga, K., Uwagawa, T., Satoskar, A. R., Gaedcke, J., Bernhardt, M., Ghadimi, B. M., Gaida, M. M., Bergmann, F., Werner, J., Ried, T., Hanna, N., Alexander, H. R., & Hussain, S. P. (2016). A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2841

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.